A clinical trial looking at the effectiveness and safety of a human plasma-derived antithrombin called Atenativ, for patients who are resistant to heparin (a blood thinner) and are undergoing cardiac surgery with cardiopulmonary bypass

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2024
This article has no abstract
Epistemonikos ID: 82fda208ee3c7a8286f5aa9964d3e85dafe6136b
First added on: Oct 25, 2024